NGGT

Executive Summary

NGGT Inc. is a private biotechnology company headquartered in Cambridge, Massachusetts, focused on developing innovative gene therapies for rare and chronic diseases, including retinal, metabolic, and neurodegenerative conditions. Founded in 2018, the company leverages a proprietary platform to target the root causes of disease. While NGGT is still in early stages with no disclosed pipeline or clinical data, its mission to address significant unmet medical needs positions it within the competitive RNA and gene therapy landscape. The company's progress and credibility will depend on achieving key developmental milestones and securing funding or partnerships in the near term.

Upcoming Catalysts (preview)

• Q3 2026Lead Program IND Filing40% success
• Q4 2026Strategic Partnership or Licensing Deal35% success
• Q2 2026Series A or B Financing Round50% success